Last updated on February 2020

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: bladder cancer | Vaginal Atrophy | Breast Cancer - HER2 Positive | Disorders of cervix NOS | Drugs | Injection Port | Lymphoma | Rectal disorder | Non-Hodgkin's Lymphoma | Diet and Nutrition | Kidney Cancer | Soft Tissue Sarcoma | Near-Sighted Corrective Surgery | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Primary Immunodeficiency | Colon Cancer Screening | Metastatic Castration Resistant Prostate Cancer | Bladder Carcinoma | Recurrent Respiratory Papillomatosis | Adverse Effects | Renal Cancer | Urologic Cancer | Anal Dysplasia | Malignant neoplasm of kidney | Chronic Diarrhea | Ovarian Cancer | Malignant Adenoma | Pancreatic Disorders | Urothelial Cancer | Uterine Cancer | Razor Bumps (Pseudofolliculitis Barbae) | Breast Cancer | Pediatric Health | Colorectal Cancer | Rectal Disorders | Pancreatic disorder | All Solid Tumors | Recurrent Ovarian Cancer | Skin Wounds | Peripheral Arterial Occlusive Disease | Bladder Disorders | Adenocarcinoma | Ovarian disorder | bladder disorder | Solid Tumors | Pancreatic Cancer | Cervical Cancer | Digestive System Neoplasms | urinary tract neoplasm | Neoplasm of unspecified nature of digestive system | Sarcoma (Pediatric) | Islet Ce417ll Cancer | Renal Cell Carcinoma | Renal Cell Cancer | Brain Function | Endometrial Cancer | Sarcoma | Squamous Cell Carcinoma of the Head and Neck | Endometrial Carcinoma | Chronic Shoulder Pain | Metastatic Triple-Negative Breast Cancer | Colon cancer; rectal cancer | Ovarian Function | Connective and Soft Tissue Neoplasm
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
  2. Documented incurable cancer with one of the following histologies: nonsmall cell lung cancer, renal cell cancer, triple negative breast cancer, colorectal cancer with microsatellite instability(MSI), bladder cancer, cervical cancer, uterine cancer, sarcoma, endometrial cancer, and metastatic castration resistant prostate cancer.
  3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
  4. For Escalation: At least 1 but not more than 5 prior systemic therapies for advanced/ recurrent or progressing disease. For Expansion: Subject must have progressed on, be refractory to, or intolerant to 1-3 prior systemic therapies.
  5. Willingness to provide tumor biopsies.

Exclusion Criteria

  1. History of severe hypersensitivity reaction to monoclonal antibodies.
  2. Subjects who have received prior therapy with regimens containing cytotoxicT-lymphocyte antigen-4 (CTLA-4), programmed cell death ligand 1 (PDL1), or PD1 antagonists are NOT permitted to enroll unless all adverse events (AEs) while receiving prior immunotherapy have resolved to Grade 1 or baseline prior to screening.
  3. History of (non-infectious) pneumonitis that required steroids or subject has current pneumonitis.
  4. The use of any investigational medication or device in the 30 days prior to screening and throughout the study is prohibited.
  5. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.